• 1
    Cramer JA, Amonkar MM, Hebborn A, Altman R 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21: 14531460.
  • 2
    Recker RR, Gallagher R, MacCosbe PE 2005 Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80: 856861.
  • 3
    Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG 2006 Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 17: 12681274.
  • 4
    Gold DT, Safi W, Trinh H 2006 Patient preference and adherence: Comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22: 23832391.
  • 5
    Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15: 10031008.
  • 6
    Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81: 10131022.
  • 7
    Huybrechts KF, Ishak KJ, Caro JJ 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38: 922928.
  • 8
    Sikka R, Xia F, Aubert RE 2005 Estimating medication persistency using administrative claims data. Am J Manag Care 11: 449457.
  • 9
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus, R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 15351541.
  • 10
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280: 20772082.
  • 11
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333340.
  • 12
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282: 13441352.
  • 13
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 8391.
  • 14
    Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, Saag KG 2006 Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf 15: 710718.
  • 15
    1980 Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 303: 10381041.
  • 16
    Ray WA, Griffin MR, Fought RL, Adams ML 1992 Identification of fractures from computerized Medicare files. J Clin Epidemiol 45: 703714.